Person · CIK 1869027

Ezbon International

10% owner at Stoke Therapeutics

Earlier: Akero Therapeutics

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$193.7M
Noticed on Form 144$41.8M
Bought on Form 4$0
Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Stoke Therapeutics STOKCommon StockSee Footnote3,906,181Jun 4, 2025 · Filing · EDGAR
Akero TherapeuticsCommon StockSee Footnote3,271,829Dec 1, 2022 · Filing · EDGAR

Sold and noticed by quarter

Ezbon International: dollars sold on Form 4 and noticed on Form 144 per quarter, Q4 2022 to Q4 2026$71.2M$0Q4 2022: notice not machine-readableQ4 2022: $71.2M sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $41.8M noticed on Form 144Q2 2024: $41.8M sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $27.2M sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $23M sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $30.6M sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $0 noticed on Form 144Q1 2026: $0 sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q4 2022Q4 2023Q4 2024Q4 2025Q4 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q2 2025$30.6M—
Q4 2024$23M—
Q3 2024$27.2M—
Q2 2024$41.8M$41.8M
Q4 2022$71.2MNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Stoke Therapeutics STOK · J.P. Morgan Securities · No 10b5-1 plan stated · 1 notice
Apr 17, 20243,600,000 · ~$41.8MApr 17, 2024Sold as noticed Sold 3,600,000 at $11.60 on Apr 17 · $41.8M Form 4Filing · EDGAR
Sales without a matching Form 144 · 4 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Stoke Therapeutics (STOK): Sold 3,000,000 at $10.20 on Jun 4, 2025 · $30.6MFiling · EDGAR
———Sold without notice Stoke Therapeutics (STOK): Sold 2,000,000 at $11.50 on Dec 23, 2024 · $23MFiling · EDGAR
———Sold without notice Stoke Therapeutics (STOK): Sold 1,937,500 at $14.05 on Sep 19, 2024 · $27.2MFiling · EDGAR
———Notice not machine-readable Akero Therapeutics: Sold 1,636,000 at $43.50 on Dec 1, 2022 · $71.2MFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Stoke Therapeutics STOK 10% owner · filings 2021 to 2025 · sold $122.6M · $41.8M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 4, 2025Open-market or private sale−3,000,000$10.20$30.6M3,906,181
See Footnote
Filing · EDGAR
Dec 23, 2024Open-market or private sale−2,000,000$11.50$23M6,906,181
See Footnote
Filing · EDGAR
Sep 19, 2024Open-market or private sale−1,937,500$14.05$27.2M8,906,181
See Footnote
Filing · EDGAR
Apr 17, 2024Open-market or private sale−3,600,000$11.60$41.8M10,843,681
See Footnote
Filing · EDGAR

Akero Therapeutics Other · filings 2021 to 2022 · sold $71.2M

DateTransactionSharesPriceValueHeld afterSource
Dec 1, 2022Open-market or private sale−1,636,000$43.50$71.2M3,271,829
See Footnote
Filing · EDGAR
All 8 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Jun 6, 2025Form 4Stoke Therapeutics STOKFiling · EDGAR
Dec 27, 2024Form 4Stoke Therapeutics STOKFiling · EDGAR
Sep 23, 2024Form 4Stoke Therapeutics STOKFiling · EDGAR
Apr 18, 2024Form 4Stoke Therapeutics STOKFiling · EDGAR
Apr 17, 2024Form 144Stoke Therapeutics STOKFiling · EDGAR
Dec 5, 2022Form 4Akero TherapeuticsFiling · EDGAR
Jun 30, 2021Form 3Akero TherapeuticsFiling · EDGAR
Jun 30, 2021Form 3Stoke Therapeutics STOKFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.